Naidoo J, Vansteenkiste JF, Faivre-Finn C, Ozguroglu M, et al. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung Cancer 2022;166:84-93.
PMID: 35245844